Caliber Imaging & Diagnostics Inc reported on Tuesday the receipt of the Food and Drug Administration's (FDA) 510(k) clearance for modifications to its non-destructive in-vivo imaging modality, the VIVASCOPE System.
The company said the VIVASCOPE System is an industry-leading reflectance confocal microscopy (RCM) device that allows dermatologists to non-invasively visualize cellular structures within the skin. The recent modifications to the system include refined ergonomics and improved imaging capabilities.
In conjunction, the company's VIVASCOPE System product portfolio has been featured by more than 800 publications. A non-destructive in-vivo imaging modality, the system painlessly provides high-resolution RCM images of the epidermis down to the supporting stroma in thin, optical slices.
Headquartered in Andover, Massachusetts, Caliber Imaging & Diagnostics Inc is a global leader in the design and manufacture of in-vivo and ex-vivo confocal microscopy equipment for the medical device, clinical research and life science industries.
TELA Bio launches LIQUIFIX for US hernia surgery
Cognizant and NVIDIA partner to revolutionize drug discovery with generative AI
Neupulse raises funds for Tourettes Syndrome wearable tech
Bonesupport gains FDA clearance for CERAMENT G in open fractures
Epitomee submits Weight Loss Capsule for FDA approval in US
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon